RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Enrollment Closed
Interventional

IGNAZ

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ

Brief Description

The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.

Email
Address

Sponsor

MorphoSys AG

Study Drug

MOR202/Felzartamab

Estimated enrollment

44

Estimated end date

Last patient last visit January 2024

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Enrollment Closed
Interventional

IGNAZ

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ

Brief Description

The IGNAZ Study is looking at the safety and effectiveness of Felzartamab in adults 18 to 80 years old with IgA nephropathy. Researchers want to compare different doses of Felzartamab to see which one might be better than taking no medicine at all.

Trial is for people with

IgA nephropathy

Study Goal

IGNAZ seeks to investigate an innovative treatment option for IgA Nephropathy

What is involved for the Patient?

During the study you would first be screened to make sure you are eligible for treatment. If so, you would be placed by chance in a group to receive one of the Felzartamab or placebo doses. A placebo looks like the study treatment but has no actual medicine in it. A placebo is used to evaluate any potential difference in the benefits and side effects of felzartamab. The medicine and placebo are given as intravenous (IV) infusions, which means they are given slowly through a small needle in the arm. Each participant would receive a total of 9 infusions. You would also continue to take your current standard medicine (for example, blood pressure pills).
The study lasts a little over 2 years with 17 visits for tests. It comprises the screening period, treatment period and follow-up period in which you will allow the sponsor to access your medical history and biosamples such as blood and urine and perhaps biopsy tissue will be collected.

About the drug or intervention

Felzartamab belongs to a group of medicines called “monoclonal antibodies”, proteins designed to attach to specific cells or substances in the body. Felzartamab is designed to attach to the cells that produce the antibody in your body and subsequently reduce unwanted auto-antibodies considered responsible for the development of IgA nephropathy.

Find other locations for this trial:
Taipei, Taiwan
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions